ArticlePloS one2025
Role of blood Krebs von Lungen-6 in predicting acute exacerbation in patients with idiopathic pulmonary fibrosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A biomarker-guided framework for corticosteroid treatment stratification in acute exacerbation of idiopathic pulmonary fibrosis.Frontiers in pharmacology · 2026Article
- Predicting and Treating Pulmonary Fibrosis with Proteomic Biomarker Investigations.Biomedicines · 2025Review
- Prognostic value of baseline serum KL-6 for mortality risk in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: A retrospective cohort study.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the role of blood Krebs von den Lungen-6 (KL-6) in predicting acute exacerbation (AE) in patients with idiopathic pulmonary fibrosis (IPF).
methodsFrom April 2018 to March 2023, clinical data of 233 IPF patients with baseline and follow-up KL-6 values at Haeundae Paik Hospital were retrospectively analyzed. AE was defined following the criteria proposed by Collard et al. in 2016.
resultsThe mean age was 71.8 years; 79% were male. During follow-up (median: 18.7 months), 33 (14.2%) patients experienced AE. Throughout the entire period from baseline, KL-6 values were higher in the AE group compared to the non-AE group (P < 0.001), and the patterns of change over time also showed significant differences between both groups (P < 0.001). The KL-6 values in the post-exacerbation phase were higher than those in the pre-exacerbation phase among the AE group (P = 0.004). The AE group showed lower 1-year (86.4% vs. 95.9%) and 3-year (50.2% vs. 91.4%) survival rates compared to the non-AE group (P < 0.001). The occurrence of AE (hazard ratio (HR) 74.09, 95% confidence interval (CI) 31.97-171.7, P < 0.001) and higher lactate dehydrogenase (HR 1.02, 95% CI: 1.01-1.02, P < 0.001) were independently associated with mortality in patients with IPF.
conclusionsOur data suggest that the trend in changes in KL-6 values may be utilized as a tool for predicting AE-IPF. Further research is needed to establish the clinical significance of changes in KL-6 for predicting AE-IPF and to validate the cut-off values for prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.